kaonavi
4435
D. Western Therapeutics Institute
4576
Itamiarts
168A
Nakayo
6715
Allied Telesis Holdings KK
6835
(Q3)Dec 31, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -10.16%30.53B | 11.81%30.08B | 2.85%129.36B | 7.32%37.3B | 6.56%33.98B | 3.40%31.18B | -7.16%26.9B | -0.89%125.77B | -6.55%34.76B | 7.27%31.89B |
Cost of revenue | -15.61%24.34B | 5.11%24.8B | 8.12%109.52B | 7.54%30.57B | 16.67%28.85B | 8.74%26.5B | -0.73%23.6B | -5.93%101.3B | -9.01%28.43B | -9.27%24.72B |
Gross profit | 20.44%6.18B | 59.76%5.28B | -18.93%19.85B | 6.32%6.73B | -28.32%5.13B | -19.06%4.68B | -36.55%3.3B | 27.29%24.48B | 6.37%6.33B | 189.80%7.16B |
Operating expense | 5.24%2.47B | 10.06%2.79B | -3.34%9.8B | -16.82%2.68B | -0.80%2.35B | -4.49%2.24B | 14.80%2.54B | 15.50%10.13B | 27.47%3.22B | 15.96%2.37B |
Operating profit | 33.26%3.71B | 224.12%2.49B | -29.94%10.05B | 30.22%4.06B | -41.92%2.78B | -28.97%2.44B | -74.41%767M | 37.18%14.35B | -9.16%3.11B | 1,017.25%4.79B |
Net non-operating interest income (expenses) | -253.57%-99M | -20.00%-6M | 81.77%-37M | 90.52%-11M | -180.00%-28M | 109.59%7M | -25.00%-5M | -63.71%-203M | -13.73%-116M | -150.00%-10M |
Non-operating interest income | 80.00%9M | -50.00%3M | 40.00%21M | -25.00%3M | 150.00%5M | 40.00%7M | 50.00%6M | 36.36%15M | 33.33%4M | -33.33%2M |
Non-operating interest expense | -20.83%19M | -18.18%9M | -7.84%47M | -36.84%12M | 166.67%24M | --0 | 37.50%11M | 45.71%51M | 58.33%19M | 80.00%9M |
Total other finance cost | ---- | ---- | -93.41%11M | -98.02%2M | ---- | ---- | ---- | 67.00%167M | 8.60%101M | 50.00%3M |
Net investment income | 872.65%904M | -2.26%650M | 148.89%1.01B | 1,053.13%305M | 83.33%-117M | -53.73%155M | -17.29%665M | -42.06%405M | -107.62%-32M | -461.86%-702M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -87.94%61M | 0 | 723.21%461M | 0.00%-16M | 583.78%506M | 0 | -29M | 205.66%56M | -16M | 355.17%74M |
Income from associates and other participating interests | -25.00%48M | 40.00%70M | -25.00%93M | -641.67%-89M | 100.00%64M | 58.14%68M | -18.03%50M | 14.81%124M | -271.43%-12M | -46.67%32M |
Special income (charges) | 4,015.00%823M | 2M | -75.12%108M | -61.22%76M | -28.57%20M | -93.94%12M | 0 | 3,000.00%434M | 880.00%196M | 2,900.00%28M |
Less:Other special charges | -4,015.00%-823M | ---2M | 75.12%-108M | 61.22%-76M | 28.57%-20M | ---- | ---- | -3,000.00%-434M | -880.00%-196M | -2,900.00%-28M |
Other non-operating income (expenses) | 34.09%118M | 700.00%112M | 38.31%343M | 305.00%41M | 15.79%88M | 86.92%200M | -83.53%14M | -82.61%248M | 95.16%-20M | -85.66%76M |
Income before tax | 67.64%5.56B | 126.59%3.32B | -21.93%12.03B | 40.10%4.36B | -22.63%3.32B | -28.77%2.89B | -63.01%1.46B | 23.00%15.41B | -7.40%3.12B | 264.49%4.29B |
Income tax | 78.58%1.94B | 235.24%1.11B | -24.39%3.59B | 19.26%1.23B | -20.70%1.09B | -17.91%935M | -72.33%332M | 18.07%4.74B | -8.75%1.03B | 219.81%1.37B |
Net income | 62.30%3.62B | 94.87%2.2B | -20.84%8.44B | 50.43%3.13B | -23.54%2.23B | -33.01%1.95B | -58.98%1.13B | 25.35%10.67B | -6.68%2.08B | 290.11%2.92B |
Net income continuous operations | 62.30%3.62B | 94.69%2.2B | -20.83%8.44B | 50.43%3.13B | -23.54%2.23B | -33.01%1.95B | -58.95%1.13B | 25.33%10.67B | -6.72%2.08B | 290.11%2.92B |
Noncontrolling interests | 105.77%6M | 28.26%-33M | 2.17%47M | 215.03%199M | -173.76%-104M | -140.00%-2M | -163.01%-46M | -54.90%46M | -765.38%-173M | 781.25%141M |
Net income attributable to the company | 54.88%3.62B | 89.89%2.24B | -20.94%8.4B | 30.02%2.93B | -15.95%2.33B | -32.83%1.95B | -56.10%1.18B | 26.33%10.62B | 2.31%2.26B | 278.85%2.78B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 54.88%3.62B | 89.89%2.24B | -20.94%8.4B | 30.02%2.93B | -15.95%2.33B | -32.83%1.95B | -56.10%1.18B | 26.33%10.62B | 2.31%2.26B | 278.85%2.78B |
Gross dividend payment | ||||||||||
Basic earnings per share | 45.95%179.07 | 81.93%112.56 | -21.02%441.04 | 29.82%153.88 | -15.94%122.69 | -32.85%102.6 | -56.16%61.87 | 26.19%558.41 | 2.14%118.53 | 278.60%145.95 |
Diluted earnings per share | 45.49%178.48 | 81.93%112.56 | -21.04%440.91 | 27.67%151.3214 | -15.95%122.6735 | -32.86%102.5956 | -56.16%61.87 | 26.19%558.41 | 2.16%118.5208 | 278.60%145.95 |
Dividend per share | 0 | 0 | 12.50%135 | 12.50%135 | 0 | 0 | 0 | 20.00%120 | 20.00%120 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |